Shi X H, Jin G
Department of Hepatobiliary Pancreatic Surgery, Changhai Hospital, Navy Military Medical University, Shanghai 200433, China.
Zhonghua Wai Ke Za Zhi. 2020 Jan 1;58(1):37-41. doi: 10.3760/cma.j.issn.0529-5815.2020.01.009.
Pancreatic cancer is the most lethal malignancy with an overall 5-year survival rate less than 9%, mainly due to late diagnosis and lack of effective therapeutic options.In the last decade, post-operative survival has been enhanced with advent of neoadjuvant therapy and combined adjuvant therapy.Furthermore, the information gained from the omics data, including next generation sequencing data, hasn't yet begun to affect treatment of pancreatic cancer patients.However, in terms of precision medicine, pancreatic cancer has always lagged behind other tumors.Therefore, combined with practical experience, summary of the latest development and research progress of precise medical treatment of pancreatic cancer, especially from the fields of molecular biology and experimental models, is of critical importance. Further development of precise medicine for pancreatic cancer based on platforms using PDX and organoid model would promisingly help in effective improvement of clinical treatment.
胰腺癌是最致命的恶性肿瘤，总体5年生存率低于9%，主要原因是诊断延迟和缺乏有效的治疗选择。在过去十年中，随着新辅助治疗和联合辅助治疗的出现，术后生存率有所提高。此外，从组学数据（包括下一代测序数据）中获得的信息尚未开始影响胰腺癌患者的治疗。然而，在精准医学方面，胰腺癌一直落后于其他肿瘤。因此，结合实际经验，总结胰腺癌精准医疗的最新发展和研究进展，特别是来自分子生物学和实验模型领域的进展，至关重要。基于使用PDX和类器官模型的平台进一步发展胰腺癌精准医学有望有效改善临床治疗。
